ロード中...
Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells
BACKGROUND: Raltegravir (Isentress®)(RALT) has demonstrated excellent efficacy in both treatment-experienced and naïve patients with HIV-1 infection, and is the first strand transfer integrase inhibitor to be approved for use in HIV infected adults worldwide. Since the in vivo efficacy of this class...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3852167/ https://ncbi.nlm.nih.gov/pubmed/24053678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2050-6511-14-47 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|